Evidence map›Paper›PMID 40933950›Full record

ArticleACS applied nano materials2025

Cancer Cell Membrane-Wrapped Nanoparticles for Photothermal Therapy and Photoacoustic Imaging of Triple-Negative Breast Cancer.

Sara B Aboeleneen, Grace M Azevedo, Kejian Li, Avery M Wolverton, Mackenzie A Scully, George C Kramarenko, Emily S Day

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied nano materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara B AboeleneenBiomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.ORCID https://orcid.org/0000-0003-1068-4349
Grace M AzevedoChemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19716, United States.
Kejian LiBiomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.
Avery M WolvertonBiomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.
Mackenzie A ScullyBiomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.ORCID https://orcid.org/0000-0001-6443-4287
George C KramarenkoBiomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.ORCID https://orcid.org/0000-0002-6990-5620
Emily S DayBiomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.ORCID https://orcid.org/0000-0002-8707-826X

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Shawn W Polson · 2012 to 2026
$67.2M
This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI FOX, JOSEPH M · 2014 to 2024
$26.8M
Vascular Consequences of Duchenne Muscular DystrophyP20GM113125 · NIGMS · UNIVERSITY OF DELAWARE · PI LENNON, SHANNON L. · 2016 to 2025
$23.3M
Understanding synovial macrophage inflamm-aging within osteoarthritisP20GM139760 · NIGMS · UNIVERSITY OF DELAWARE · PI DAWN M ELLIOTT · 2021 to 2026
$19.1M
Pilot Research Subproject ProgramP30GM110758 · NIGMS · UNIVERSITY OF DELAWARE · PI POLENOVA, TATYANA · 2014 to 2018
$5.8M
Multifunctional siRNA/antibody nanocarriers to treat metastatic triple-negative breast cancerR01CA211925 · NCI · UNIVERSITY OF DELAWARE · PI DAY, EMILY S · 2019 to 2023
$1.7M
Zeiss LSM710 Inverted Confocal MicroscopeS10OD016361 · OD · UNIVERSITY OF DELAWARE · PI CAPLAN, JEFFREY L · 2015 to 2015
$444k
NCI NIH HHS R01 CA211925NIGMS NIH HHS P20 GM103446NIGMS NIH HHS P20 GM104316NIGMS NIH HHS P20 GM113125NIGMS NIH HHS P20 GM139760NIGMS NIH HHS P30 GM110758NIH HHS S10 OD016361
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive and challenging subtypes of breast cancer to treat, primarily due to a lack of targeted therapies. Photothermal therapy (PTT) has emerged as a promising noninvasive strategy, wherein systemically administered light-responsive nanoparticles accumulate at the tumor site and convert externally applied near-infrared light into heat, culminating in tumor ablation. Nonetheless, the clinical application of PTT is impeded by insufficient nanoparticle accumulation within tumors. We present the development of silica core/gold shell nanoshells that are coated with TNBC cell membranes (MWNS) to enhance tumor accumulation through homotypic recognition and immune evasion. We demonstrate that MWNS preferentially target 4T1 TNBC cells over EpH4-Ev noncancerous breast epithelial cells

Indexed as

biomimicrycontrast agenthyperthermiananomedicineoncologytheranostic

Identifiers

PMID40933950
PMCPMC12418301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.